You are here

Home » Company Details

21ST CENTURY THERAPEUTICS, INC.

Company Information
Address
440 BURROUGHS ST STE 100
DETROIT, MI 48202-3428
United States
Information

UEI: YR4CUFNLGKL8

# of Employees: 9
Ownership Information

HUBZone Owned: Yes

Socially and Economically Disadvantaged: No

Woman Owned: No

Award Charts




Award Listing

  • Record 1 TO 4

  1. Development of a novel small molecule, UTL-5g, to treat oxaliplatin-induced throm

    Amount: $276,418.00

    DESCRIPTION (provided by applicant): Although oxaliplatin is a third-generation platinum drug, it has become the most prescribed amongst all platinum drugs overtaking its predecessors, cisplatin and c ...

    SBIRPhase I2013Department of Health and Human Services National Institutes of Health

  2. Novel small-molecule TNF-a modulators as chemoprotective agents

    Amount: $1,133,678.00

    DESCRIPTION (provided by applicant): Cisplatin is a widely used cytotoxic agent with therapeutic activity against various tumors, but also with substantial side effects, including nephrotoxicity, hepa ...

    SBIRPhase II2011Department of Health and Human Services National Institutes of Health

  3. TAS::75 0849::TAS

    Amount: $186,857.00

    Radiotherapy can potentially inflict serious damage on healthy normal organs. For example, pneumonitis and fibrosis are two well-recognized adverse effects from lung cancer radiotherapy: Currently, am ...

    SBIRPhase I2011Department of Health and Human Services National Institutes of Health

  4. Novel Small-molecule TNF-a Modulators as Chemoprotective Agents

    Amount: $154,852.00

    DESCRIPTION (provided by applicant): Cisplatin is a widely used cytotoxic agent with therapeutic activity against various tumors, but also with substantial side effects, including nephrotoxicity, hepa ...

    SBIRPhase I2009Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government